AnaptysBio - Overview
About
Overview
Strategy
Senior Leadership
Board of Directors
Scientific Advisory Board
Contact
Science
Immune Cell Modulation
Publications
Pipeline
Overview
Rosnilimab
ANB032
ANB033
ANB101
Imsidolimab
Partnerships
Investors / News
Overview
News
Events
Presentations
Goverance
Stock Information
Analyst Coverage
SEC Filings
Investor FAQs
Contact
Careers
Overview
Job Openings
Core Values
Total Rewards Program Highlights
AnaptysBio Culture
Contact
Toggle
Overview
Rosnilimab
Overview
Rheumatoid Arthritis
Ulcerative Colitis
ANB032
Overview
Atopic Dermatitis
ANB033
ANB101
Imsidolimab
Partnerships
Pipeline
Development Stage and Anticipated Milestones
Antibody
Program
Therapeutic
Indication
Lead Optimization
IND Enabling
Phase 1
Phase 2
Phase 3
ANB032
(BTLA agonist)
Atopic Dermatitis
P2b initiated Q2 2023
Top-line data YE 2024
Rosnilimab
(PD-1 agonist)
P2b initiated Q4 2023
Top-line data H1 2026
ANB033
(CD122 antagonist)
Inflammatory Diseases
Ulcerative Colitis
Rheumatoid Arthritis
IND Submission
Q2 2024
ANB101
(BDCA2 modulator)
Inflammatory Diseases
IND Submission
H2 2024
P2b initiated Q2 2023
Top-line data mid 2025
Immune Cell Modulators
Generalized Pustular
Psoriasis (GPP)
Submit data abstract to
med meeting in H2 2024
GEMINI-1 BLA Q3 2024
Etokimab
(IL-33 antagonist)
Respiratory Disorders
P2b/3-ready
Out-license in 2024
No further internal investment
Legacy Programs Available for Outlicensing
Cytokine Antagonists
Imsidolimab
(IL-36R antagonist)